Literature DB >> 10783936

The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.

L Jacobson1, P Hertzman, C G Löfdahl, B E Skoogh, B Lindgren.   

Abstract

This study was carried out to estimate the direct and indirect costs associated with asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991, and to identify trends in the use of outpatient care, drugs and inpatient care, and the development of temporary morbidity, permanent disability and mortality for asthma and COPD. Routinely published administrative and population data were used to estimate the costs of asthma and COPD, and these figures were compared to corresponding estimates and trends for all respiratory diseases as well as for all diseases. Asthma and COPD each accounted for about SEK 3 billion, together roughly 2% of the economic cost of all diseases. Although the total costs associated with each disease were similar, the distribution of the different cost components and changes in each component over time differed. During the 1980s, the cost of drugs and out-patient care increased for both diseases. The cost of inpatient care for asthma decreased, whereas that for COPD increased. This study shows that asthma therapy has changed from inpatient to ambulatory care in Sweden, while the treatment of COPD to a higher degree still is based on inpatient care.

Entities:  

Mesh:

Year:  2000        PMID: 10783936     DOI: 10.1053/rmed.1999.0733

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  COPD patients' rights: Can they be won?

Authors:  Larry Grouse
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

2.  Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD.

Authors:  Maher R Khdour; Ashley M Agus; Joseph C Kidney; Bronagh M Smyth; James C McElnay; James C Elnay; Grainne E Crealey
Journal:  Int J Clin Pharm       Date:  2011-06-04

Review 3.  Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.

Authors:  A Markham; J C Adkins
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

Review 4.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Socioeconomic impact of asthma, chronic obstructive pulmonary disease and asthma-COPD overlap syndrome.

Authors:  Jinhee Kim; Young Sam Kim; Kyungjoo Kim; Yeon-Mok Oh; Kwang Ha Yoo; Chin Kook Rhee; Jin Hwa Lee
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

6.  [Direct costs to primary care of chronic bronchitis. Analysis of a prospective study].

Authors: 
Journal:  Aten Primaria       Date:  2001-04-15       Impact factor: 1.137

7.  Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma.

Authors:  Bernd Brüggenjürgen; Dagmar Selim; Peter Kardos; Kai Richter; Claus Vogelmeier; Stephanie Roll; Wolfgang Meyer-Sabellek; Roland Buhl; Stefan N Willich
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

9.  Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Cayo García-Polo; Adolfo Domenech; Gustavo Villegas; Francisco Conget; Cristian de la Roza
Journal:  Lung       Date:  2013-07-11       Impact factor: 2.584

10.  Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost.

Authors:  Kyle Darnell; Alok Kumar Dwivedi; Zhouyang Weng; Ralph J Panos
Journal:  Cost Eff Resour Alloc       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.